Acrivon Therapeutics (ACRV) Competitors

Acrivon Therapeutics logo
$1.43 -0.03 (-2.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.48 +0.05 (+3.50%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACRV vs. RCKT, ARCT, DTIL, BCYC, and ALPS

Should you buy Acrivon Therapeutics stock or one of its competitors? Acrivon Therapeutics's main competitors and comparable companies include Rocket Pharmaceuticals (RCKT), Arcturus Therapeutics (ARCT), Precision BioSciences (DTIL), Bicycle Therapeutics (BCYC), and ALPS Group Inc Ordinary Share (ALPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Acrivon Therapeutics compare to Rocket Pharmaceuticals?

Acrivon Therapeutics (NASDAQ:ACRV) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A
Rocket PharmaceuticalsN/AN/A-$223.12M-$0.15N/A

In the previous week, Rocket Pharmaceuticals had 5 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 11 mentions for Rocket Pharmaceuticals and 6 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.73 beat Rocket Pharmaceuticals' score of 0.18 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Acrivon Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rocket Pharmaceuticals
2 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Acrivon Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market. Comparatively, Rocket Pharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market.

Acrivon Therapeutics currently has a consensus target price of $13.50, indicating a potential upside of 844.06%. Rocket Pharmaceuticals has a consensus target price of $7.77, indicating a potential upside of 268.35%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Rocket Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Rocket Pharmaceuticals
2 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.42

Rocket Pharmaceuticals' return on equity of -51.84% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Acrivon TherapeuticsN/A -75.22% -65.85%
Rocket Pharmaceuticals N/A -51.84%-43.04%

Summary

Rocket Pharmaceuticals beats Acrivon Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Arcturus Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Acrivon Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the broader market. Comparatively, Arcturus Therapeutics has a beta of 2.62, suggesting that its share price is 162% more volatile than the broader market.

Acrivon Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -285.92%. Arcturus Therapeutics' return on equity of -46.79% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Acrivon TherapeuticsN/A -75.22% -65.85%
Arcturus Therapeutics -285.92%-46.79%-36.50%

Acrivon Therapeutics presently has a consensus price target of $13.50, suggesting a potential upside of 844.06%. Arcturus Therapeutics has a consensus price target of $24.50, suggesting a potential upside of 207.40%. Given Acrivon Therapeutics' higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Arcturus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.00

Arcturus Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A
Arcturus Therapeutics$82.03M2.80-$65.78M-$3.08N/A

In the previous week, Acrivon Therapeutics had 1 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 5 mentions for Arcturus Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.73 beat Arcturus Therapeutics' score of 0.49 indicating that Acrivon Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Acrivon Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 17.8% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Arcturus Therapeutics beats Acrivon Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Precision BioSciences?

Precision BioSciences (NASDAQ:DTIL) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Precision BioSciences has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

In the previous week, Acrivon Therapeutics had 6 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 0 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.91 beat Acrivon Therapeutics' score of 0.73 indicating that Precision BioSciences is being referred to more favorably in the media.

Company Overall Sentiment
Precision BioSciences Positive
Acrivon Therapeutics Positive

Precision BioSciences presently has a consensus price target of $32.25, suggesting a potential upside of 357.45%. Acrivon Therapeutics has a consensus price target of $13.50, suggesting a potential upside of 844.06%. Given Acrivon Therapeutics' higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Precision BioSciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision BioSciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Precision BioSciences has higher revenue and earnings than Acrivon Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$34.26M5.75-$45.72M-$1.24N/A
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A

Acrivon Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Precision BioSciences' return on equity of -56.69% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Precision BioSciences-96.73% -56.69% -27.63%
Acrivon Therapeutics N/A -75.22%-65.85%

Summary

Precision BioSciences and Acrivon Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and risk.

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Bicycle Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.96, meaning that its stock price is 96% more volatile than the broader market.

In the previous week, Bicycle Therapeutics and Bicycle Therapeutics both had 6 articles in the media. Bicycle Therapeutics' average media sentiment score of 0.95 beat Acrivon Therapeutics' score of 0.73 indicating that Bicycle Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bicycle Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Acrivon Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bicycle Therapeutics presently has a consensus target price of $13.57, suggesting a potential upside of 324.11%. Acrivon Therapeutics has a consensus target price of $13.50, suggesting a potential upside of 844.06%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Bicycle Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bicycle Therapeutics
1 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.40
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Acrivon Therapeutics has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bicycle Therapeutics$72.86M3.08-$218.96M-$2.03N/A
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A

Acrivon Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -169.75%. Bicycle Therapeutics' return on equity of -26.02% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bicycle Therapeutics-169.75% -26.02% -22.30%
Acrivon Therapeutics N/A -75.22%-65.85%

Summary

Bicycle Therapeutics beats Acrivon Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Acrivon Therapeutics compare to ALPS Group Inc Ordinary Share?

ALPS Group Inc Ordinary Share (NASDAQ:ALPS) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 0.8% of ALPS Group Inc Ordinary Share shares are held by company insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Acrivon Therapeutics has a consensus target price of $13.50, suggesting a potential upside of 844.06%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than ALPS Group Inc Ordinary Share.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALPS Group Inc Ordinary Share
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat Acrivon Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ALPS Group Inc Ordinary ShareN/A N/A N/A
Acrivon Therapeutics N/A -75.22%-65.85%

ALPS Group Inc Ordinary Share has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.96, suggesting that its stock price is 96% more volatile than the broader market.

In the previous week, Acrivon Therapeutics had 5 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 6 mentions for Acrivon Therapeutics and 1 mentions for ALPS Group Inc Ordinary Share. ALPS Group Inc Ordinary Share's average media sentiment score of 0.92 beat Acrivon Therapeutics' score of 0.73 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ALPS Group Inc Ordinary Share
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Acrivon Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ALPS Group Inc Ordinary Share has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ALPS Group Inc Ordinary Share$4.86M7.63-$2.01M$0.264.50
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A

Summary

Acrivon Therapeutics beats ALPS Group Inc Ordinary Share on 7 of the 13 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ACRV vs. The Competition

MetricAcrivon TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$62.57M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-0.7825.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book0.404.184.463.72
Net Income-$77.90M-$24.15M$3.52B$393.10M
7 Day Performance-8.92%-7.25%-5.47%-4.73%
1 Month Performance-12.80%-5.98%-4.57%-7.14%
1 Year Performance-39.92%-7.72%-1.79%-7.51%

Acrivon Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACRV
Acrivon Therapeutics
3.4519 of 5 stars
$1.43
-2.1%
$13.50
+844.1%
-34.8%$62.57MN/AN/A76
RCKT
Rocket Pharmaceuticals
3.2865 of 5 stars
$2.45
-3.2%
$7.77
+217.2%
-29.2%$268.96MN/AN/A202
ARCT
Arcturus Therapeutics
2.7841 of 5 stars
$9.39
-1.1%
$22.29
+137.3%
+14.3%$266.86M$82.03MN/A111
DTIL
Precision BioSciences
3.3688 of 5 stars
$9.50
-1.9%
$32.25
+239.5%
+23.8%$265.43M$34.26MN/A67
BCYC
Bicycle Therapeutics
2.7566 of 5 stars
$3.69
-2.1%
$13.57
+267.8%
-50.9%$258.26M$72.86MN/A288

Related Companies and Tools


This page (NASDAQ:ACRV) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners